{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 87 of 129', 'The applied estimands incorporate two main types of events that influence how the treatment', 'effects are estimated:', 'Initiation of rescue medication: Some of the estimands use the initiation of rescue', 'medication as an event that modifies the applied value of an endpoint, e.g. by defining a', 'subject receiving rescue medication as a non-responder.', 'Permanent discontinuation of IMP: This event occurs when a subject is permanently', 'withdrawn from the treatment or the trial as described in section 8.5. This can either', \"happen at his/her own initiative or at the investigator's discretion. The event also includes\", 'the possibility of a subject being lost to follow-up. The timing of the event is defined as', 'the date of the early termination visit for withdrawn subjects or - in the case of a subject', 'lost to follow-up - the date of the last known visit to the clinic. As for the rescue', 'medication, the event type is used to modify an applied endpoint value.', 'All analyses will be based on the full analysis set unless otherwise specified.', '12.3.5.1 Primary estimand: \"composite\\'', 'The primary estimand for the primary endpoints will be:', 'Treatment difference in response rates of IGA 0/1 and EASI75 after 16 weeks', 'achieved without rescue medication, regardless of treatment discontinuation.', 'The primary estimand assesses the expected difference in response rates (defined as response', 'obtained without initiation of any rescue medication) after 16 weeks, resulting from initiation', 'of a treatment regimen with tralokinumab+TC compared to a treatment regimen with', 'placebo+TCS.', 'Primary analysis for the primary estimand', 'Data retrieved at Week 16 for subjects who have permanently discontinued IMP prior to', 'Week 16 will be included in the analysis. Subjects who prior to the Week 16 visit have', 'received rescue medication will be considered non-responders, reflecting an assumption that', 'initiation of rescue medication indicates failure of the randomised treatment to achieve', 'response, and that a (possible) observed positive response after initiation of rescue medication', 'is not attributable to the randomised treatment. Missing data for subjects who do not attend', 'the Week 16 visit and where rescue medication has not been used prior to Week 16, will be', 'imputed as non-responders.', 'The difference in response rates between treatment groups will be analysed using the', 'Cochran-Mantel-Haenszel test stratified by region (Europe and North America) and baseline', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 88 of 129', 'disease severity (IGA 3 or 4). The treatment estimate and the corresponding 95% CI will be', 'presented. The null hypothesis of no difference in response rates between tralokinumab+TCS', 'and placebo+TCS will be tested against the 2-sided alternative that there is a difference.', 'The primary endpoints will be tested sequentially at a 5% significance level. IGA 0/1 will be', 'tested first, and, if significant, then EASI75 will be tested. If both primary null hypotheses are', 'rejected, the secondary endpoints will be tested.', 'Sensitivity analyses for the primary estimand', 'Two sensitivity analyses are specified for the primary estimand. In both cases the same', 'Cochran-Mantel-Haenszel test as used for the primary analysis will be applied including', 'stratification by region and baseline disease severity.', 'The purpose of the analyses is to assess the robustness of results of the primary analysis with', 'respect to the retrieved data at Week 16 and assumptions regarding missing Week 16 data.', 'Sensitivity analysis 1: All subjects who have permanently discontinued IMP prior to Week 16', 'will be imputed as non-responders, even if no rescue medication has been used. This is to', 'reflect a situation where retrieved efficacy data and concomitant medications could be', 'registered less accurately for subjects who have discontinued treatment.', 'Sensitivity analysis 2: Rather than imputing all subjects who do not attend the Week 16 visit', 'and where rescue medication has not been used as non-responders, the following approach', 'will be applied. If subjects have withdrawn due to an AE or due to lack of efficacy, they are', 'still considered non-responders. Data missing for other reasons will be imputed using last', 'observation carried forward (LOCF), hereby assuming that the last value is a more reliable', 'estimate of the missing response (than a non-response).', 'Supplementary analysis', 'The primary analysis of the primary estimand is repeated based on the per protocol analysis', 'set.', '12.3.5.2 Secondary estimand: \"hypothetical\\'', 'The secondary estimand for the primary endpoints will be:', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}